Regeneron Logo.jpg
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
13 janv. 2025 06h30 HE | Regeneron Pharmaceuticals, Inc.
Regeneron shares corporate progress and highlights from the Company’s broad and diverse investigational pipeline.
Regeneron Logo.jpg
Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
13 janv. 2025 06h15 HE | Regeneron Pharmaceuticals, Inc.
Primary endpoint of DFS met at first prespecified interim analysis, showing a 68% reduction in the risk of disease recurrence or death in patients with high-risk CSCC after surgery compared to placebo...
Regeneron Logo.jpg
Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
13 janv. 2025 06h05 HE | Regeneron Pharmaceuticals, Inc.
The Truveta collaboration will extend Regeneron Genetics Center’s® (RGCTM) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers)...
Regeneron Logo.jpg
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
07 janv. 2025 16h05 HE | Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating...
Regeneron Logo.jpg
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
19 déc. 2024 07h00 HE | Regeneron Pharmaceuticals, Inc.
Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations...
Regeneron Logo.jpg
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
17 déc. 2024 16h05 HE | Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday,...
Regeneron Logo.jpg
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
17 déc. 2024 07h00 HE | Regeneron Pharmaceuticals, Inc.
EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 weeks Safety data remains consistent with the known...
Regeneron Logo.jpg
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
16 déc. 2024 16h30 HE | Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI...
Regeneron Logo.jpg
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
09 déc. 2024 17h45 HE | Regeneron Pharmaceuticals, Inc.
Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results from the safety lead-in portion of the...
Regeneron Logo.jpg
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
07 déc. 2024 19h00 HE | Regeneron Pharmaceuticals, Inc.
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate...